Stock Ratings / Health Care / SANA / forecast

DNA (35) ATTO (44) PRME (30) SLBT (45) ⌘ Pro Terminal →

Sana Biotechnology Inc. (SANA) 12-Month Stock Forecast & Price Target Cone

$2.57 -5.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.54

Sana Biotechnology Inc. (SANA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $769.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SANA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Sana Biotechnology Inc. (NASDAQ: SANA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.57 (-5.51% 1D, market cap $769.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SANA ranks #672 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SANA compare to DNA and ATTO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SANA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DNA (Ginkgo Bioworks Holdings Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $721.3M) and ATTO (Attovia Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $693.4M). Among the 5-stock peer group, SANA leads on earnings multiple (N/A) while SANA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SANA?

▼

Per SANA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770121), Sana Biotechnology Inc. generated $0 in revenue, -$244.2M in net income, and -$144.8M in free cash flow against $416.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.54 (-1.18%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SANA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY SANA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.41-2.1% Next Q

Q2 (-2Q)

Grade E$2.36+4.7% Next Q

Q3 (-1Q)

Grade E$2.47+4% Next Q

Current

Grade E$2.57-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SANA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SANA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.99) and Max Pain ($2.70) forces dealer call-delta covering toward $5.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SANA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SANA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SANA Position Size: $10,000

Shares at $2.57: 3891.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.78

$6,926

$-3,074 (-30.7%)

12M Consensus BaseTarget $2.28

$8,872

$-1,128 (-11.3%)

12M Bull Case BreakoutTarget $5.76

$22,412

+$12,412 (+124.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$5	69%	B
JP MorganUS Large-Cap Research	SELL	$2	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SANA)

✓Walkthrough of SANA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SANA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.63%📐 HORIZONTAL RANGE

2026-11-03O $2.72H $2.72L $2.57C $2.57VOL 2.08M

RES: $4.23SUP: $2.06SMA50: $2.99SMA200: $3.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SANA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SANA Butterfly Map → + Track SANA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SANA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SANA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SANA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SANA)

Health Care Rank #672 of 1016 ⚔️ DNA vs SANA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SANA vs. DNA, ATTO, PRME, SLBT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sana Biotechnology Inc. (SANA) ranks #672 by composite RQD confidence (33/100, grade E) and #387 by equity capitalization ($769.4M). Within this direct 5-issuer industry benchmark cohort, SANA leads on earnings valuation at N/A trailing P/E, while SANA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with SANA at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SANA ACTIVE Sana Biotechnology Inc.	E	33/100	—	—	-35.0%	-5.51%	$769.4M	Benchmark Subject
DNA Ginkgo Bioworks Holdings Inc. (Class A)	D-	35/100	—	—	-35.0%	-12.01%	$721.3M	/dna-vs-sana →
ATTO Attovia Therapeutics Inc.	D	44/100	—	—	—	-0.52%	$693.4M	/atto-vs-sana →
PRME Prime Medicine Inc.	E	30/100	—	—	-35.0%	-9.92%	$856.1M	/prme-vs-sana →
SLBT SL Science Holding Limited	D	45/100	—	—	—	+2.56%	$672.9M	/slbt-vs-sana →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770121

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sana Biotechnology Inc. (SANA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$244.2M, operating cash flow of -$143.8M, and free cash flow of -$144.8M (+43.6% YoY). On the balance sheet, SANA closed FY2025 with $416.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$244.2M	-$143.8M	-$144.8M	$416.9M	—
FY2024 (FY)	2024-12-31	$0	-$266.8M	-$223.2M	-$256.6M	$501.0M	—
FY2023 (FY)	2023-12-31	$0	-$283.3M	-$253.6M	-$253.6M	—	—

3. SANA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SANA compare to DNA and ATTO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SANA?

Where is SANA trading relative to its 50-day, 200-day, and 52-week technical levels?

SANA last traded at $2.57 (-5.51% on volume of 2,076,894 shares), positioning the stock -14.05% below its 50-day simple moving average ($2.99) and -23.74% below its 200-day simple moving average ($3.37). Across its 52-week range of $2.22 to $5.49, SANA sits at the 10.7% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.25 to $2.89).

SANA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SANA's 12-month stock price target?

Sana Biotechnology Inc. (SANA) carries a 12-month consensus base price target of $2.28 (-11.3% from $2.57), with a bull-case target of $5.76 and a bear-case floor of $1.78.

Is SANA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SANA E (Strong Sell — SELL) with an RQD Confidence score of 33/100.

Direct Sub-Reports: SANA RQD Cockpit SANA 12M Forecast SANA Earnings & Move SANA Dividends & DRIP SANA Insiders & 13F SANA Whale Options SANA Profit Sankey SANA News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SANA — Sana Biotechnology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:40Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SANA carries an RQD Score of 33 out of 100, a letter grade of E, and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine (9 / 20): Per the RQD rating, this reflects ROIC of -35% and an FCF yield of -17.78%. For a prospective investor, the score signals that the business is not currently generating returns on capital or free cash flow.
Whale 13F Flow (5 / 20): Per the RQD rating, this pillar covers institutional accumulation and options positioning. The score is low, which indicates weak institutional support in the source data.
Insider Conviction (3 / 20): Per the RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar, indicating weak insider conviction signals.
Macro Regime Fit (6 / 20): Per the RQD rating, this reflects Beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock moves in line with the market, with no defensive cushion indicated in the data.
Forensic Balance Sheet (10 / 20): Per the RQD rating, this reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. This is the highest pillar, but it remains weak in absolute terms.

For a prospective investor evaluating the stock today, the combined pillars point to a profile of ongoing losses, negative cash generation, weak institutional and insider signals, and a forensic balance sheet that is not strong. Upside drivers present in the source data are limited to the price action and news flow described below; valuation tradeoffs cannot be assessed because P/E and EV/EBITDA are not available in source data. This section is analytical and educational, not personalized financial advice.

Open Questions

What are the company's products, indications, and revenue model, given that every reported period shows $0.0M revenue?
What is the cash runway implied by the $71.9M cash balance against the FY 2025 FCF of $-144.8M, and what financing is planned?
What were the FY 2023 cash and debt balances, and what is the company's current debt position?
What do the Form 4 filings referenced in the news show regarding insider transactions?
What are the EPS and valuation multiples (P/E, EV/EBITDA) that would allow a relative valuation assessment?

SANA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sana Biotechnology Inc. (SANA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SANA Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 16h ago

Sana Biotechnology: A Shot At Diabetes

Seeking Alpha report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 19h ago

Sana Biotechnology, Inc. Estimates – NASDAQ:SANA

TradingView report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Nigeria • 22h ago

Form 4 Sana Biotechnology Inc For: 11 October By Investing.com

Investing.com Nigeria report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

Sana Biotechnology trades at a discount despite promising early T1D treatment data and limited cash runway.

Pluang report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Sana Biotechnology (SANA) Slips 8% to $2.41 as Shares Retreat Toward Key Support - Dividend ETF

https://www.dars.gov.et/ report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Sana Biotechnology (SANA) Trades Flat at $2.89, Consolidating Between Key Levels - Retail Sentiment

https://www.siam.in/ report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

SANA Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Focus on Cash Discipline - Dividend Cut Risk

https://www.dars.gov.et/ report covering Sana Biotechnology Inc. (SANA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SANA Bull vs. Bear Conversation Board — What's Your Call at $2.57?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SANA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.39 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SANA (E • RQD 33/100) a Buy at $2.72?

Welcome to the SANA (Sana Biotechnology Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.15 (-21.0%)

Spot @ $2.72

Pump the brakes on SANA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SANA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sana Biotechnology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.10 (+14.0%)

Spot @ $2.72

SANA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SANA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.72 (52-wk range $2.22 - $5.49), any beat on forward guidance forces shorts and underweight funds to chase.